Release – Onconova Therapeutics (ONTX) – Reports 2020 Full Year Financial Results


Onconova Therapeutics Reports Full Year 2020 Financial Results, Provides Business Update

 

Conference call begins at 4:30 p.m. Eastern time today

NEWTOWN, Pa., March 11, 2021 (GLOBE NEWSWIRE) — Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for patients with cancer, announces financial results for the twelve months ended December 31, 2020 and provides a business update.

Highlights of the fourth quarter of 2020 and recent weeks include:

  • ON 123300, Onconova’s proprietary multi-kinase inhibitor, received clearance from the U.S. Food and Drug Administration (FDA) to begin Phase 1 studies
  • ON 123300 also received Institutional Review Board (IRB) approval at one U.S. clinical trial site
  • The Phase 1 solid tumor study with ON 123300 in China is ongoing and continues to enroll patients
  • Raised net proceeds of $35.2 million from two equity offerings; cash and cash equivalents as of February 28, 2021 were approximately $49.5 million
  • An independent investigator-initiated study with oral rigosertib in combination with a PD-1 inhibitor in advanced KRAS mutated non-small cell lung cancer is ongoing
  • A Special Meeting of Stockholders to consider changes to the capital structure of the Company will reconvene on April 1, 2021

Management Commentary

“The fourth quarter and recent weeks have been active and productive at Onconova as we continue to advance our lead product ON 123300 into the clinic,” said Steven M. Fruchtman, M.D., President and Chief Executive Officer of Onconova. “We submitted an Investigational New Drug application to the FDA for a Phase 1 study in advanced cancers including HR+/HER 2- metastatic breast cancer patients resistant to approved second-generation CDK 4/6 inhibitors. In December 2020, we received clearance from the FDA to begin the study, and have since received IRB approval at our first site. We expect the first patient to be enrolled in the second quarter of this year. Two further sites are in the study set-up process.

“This Phase 1 study will assess the safety, tolerability and pharmacokinetics of ON 123300 administered orally at increasing doses starting at 40 mg daily continuously.

“Our partner in China, HanX Pharmaceuticals, continues enrolling a similar patient population in a Phase 1 dose-escalation study with ON 123300 at two sites. The initial dose cohort has been completed and the second dose cohort is enrolling. We are pleased that ON 123300 appears to be well tolerated so far as no dose-limiting toxicities have been seen to date. The HanX study is dosing patients on a 21-day cycle. Collectively, the U.S. and China Phase 1 studies are expected to provide data regarding the safety profile of ON 123300 and potentially provide preliminary efficacy signals in patients with advanced cancer.”

Commenting on ongoing investigator-sponsored studies with oral rigosertib, the company’s RAS pathway inhibitor, Dr. Fruchtman added, “We are currently supporting investigator-initiated studies that are exploring the use of oral rigosertib for cancers driven by mutation of the RAS gene including a Phase 1 study in combination with a PD-1 inhibitor for patients with progressive K-RAS mutated non-small cell lung cancer. This study is open and continues to enroll patients, with the objectives to identify the recommended Phase 2 dose and to characterize the safety profile of the combination treatment. Results are expected in 2021.

“In addition, an investigator-initiated Phase 1b/2 study with oral rigosertib monotherapy in advanced squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa is open. A preclinical study is also evaluating oral rigosertib in clear cell renal carcinoma. We anticipate additional investigator-initiated studies in RAS-driven cancers in combination with PD-1 inhibitors, including in metastatic melanoma. Other than the cost of supplying oral rigosertib to the investigators, Onconova does not expect to incur significant expense for these studies,” Dr. Fruchtman stated.

View the full press release at Onconova’s website: investor.onconova.com/

Company Contact:
Avi Oler
Onconova Therapeutics, Inc.
267-759-3680

ir@onconova.us
https://www.onconova.com/contact

Investor Contact:
LHA Investor Relations
Kim Sutton Golodetz
212-838-3777

kgolodetz@lhai.com

SOURCE: Onconova Therapeutics, Inc.

Comstock Mining (LODE) – Taking Stock of 2020 and Looking Ahead

Friday, March 12, 2021

Comstock Mining (LODE)
Taking Stock of 2020 and Looking Ahead

Comstock Mining Inc. is an emerging innovator and leader in the sustainable extraction, valorization, and production of scarce natural resources, with a focus on high value strategic materials that are essential to meeting the rapidly increasing global demand for clean energy, carbon-neutrality, and natural products.

Mark Reichman, Senior Research Analyst of Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    A year of accomplishment. Comstock Mining hosted a well-attended Zoom meeting to discuss 2020 operational activities and the outlook for 2021. While the accomplishments are almost too numerous to mention, the company set the stage for the completion of an SK-1300 compliant resource estimate for the Dayton-Spring Valley resource in 2021, advanced its mercury remediation and gold extraction operations in the United States and Philippines, and enhanced its financial flexibility with the sale of the Lucerne project while retaining royalty interests. All facets of the company’s operations were positioned to create value for shareholders in the years ahead.

    Transforming the business model.  While Comstock is advancing its silver and gold resources in Nevada, the company’s investments in strategic metals recovery, including lithium-ion battery recycling and mercury remediation and gold extraction, could significantly accelerate revenue and cash flow growth …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

About Marijuana Investments

 


The Future of Cannabis Crosses Many Industries

 

Companies related to cannabis products in the U.S. and Canada attract a lot of attention from investors. This is not a surprise as marijuana is a welcome addition to varied industries, most with growing demand and high potential. It’s expected that the rapid growth of acceptance and benefits from cannabis products are just being realized. Investing in a high-growth area while it is still in its infancy is an investment strategy we can all understand.

According to Precedence Research, it’s expected that the global legal marijuana market size was at $USD 17.5 billion in 2019 and is predicted to reach $USD 65.1 billion by 2027. The global legal cannabis market is expected to expand at a compound annual growth rate of around 17.8% during the forecast period 2020 to 2027. This information, as positive as it is for investors, is far too broad to be very useful. This is because there are distinct and very different businesses that fall under the umbrella of cannabis stocks.

Primary Cannabis Businesses

As with almost any raw material, there are many different uses. Businesses discover different uses for the benefit of the consumer and of course their bottom line to use the same commodity. For example, the dairy industry provides milk that is used in hundreds of other products, both food and otherwise. Petroleum is used for everything from food, to plastic, to fuel. And glass is manufactured for everything from windshields to fiber-optic cable. As far as cannabis is concerned, it’s presumed that within the medical field and recreational uses the benefits of this fast-growing resource have, to date, barely been defined. The power of the motives, which include to help others (medical), please others (recreational), and make money (business) have yet to be fully explored and unleashed. This process has been muddied by regulations that are still roadblocks – roadblocks that are presumed to be going away over an unspecified time period.

The business and investment opportunities come under the headings, growers, dispensaries, distributors, biotech or medical, recreational, and ancillary products and services. 

Drilling Down

To Define companies doing business in the various cannabis fields more clearly as an investment opportunity, growers are the easiest to understand. Most medical, nutritional, and recreational companies are not self-sourced. Cultivators such as Auxly Cannabis Group, Inc. (XLY:CA) which operates primarily in Canada and Uruguay is involved in refining strains and bringing product to medical, wellness, and recreational companies.

Providing ancillary products avoids some of the banking restrictions put on companies actually producing or handling cannabis products. KushCo Holdings, Inc. (KSHB) focuses on providing businesses with vaporizers, solvents, branding consultancy, and packaging to businesses in the regulated medical and recreational cannabis and hemp industries.

Another company that would be categorized as ancillary is Stem Holdings, Inc. (STMH). They purchase, improve, and lease properties and finance assets that are operated by third parties and used for cultivation, retail sale of cannabis products, and manufacture, distribution, and branding of cannabis-infused products.

Companies that are broad-based and vertically integrated offer more diversification than those more narrowly focused. Medicine Man Technologies, operating under the name Schwazze (SHWZ) meets those criteria for investors looking to explore companies involved across several cannabis businesses. They have a portfolio of top licensed brands which span cultivation, extraction, infused manufacturing, dispensary operations, consulting, and nutrient lines. An outperform rating was recently given to Schwazze stock by Noble Capital Markets. The report is available at no cost to registered Channelchek users.

 

 

Known Risk to Investing in Cannabis Stocks

This is certainly not a complete list, but there are three primary risks in this industry. They are: legal restrictions, valuation, and commoditization.

In the U.S., marijuana is legal in many states but not yet legal at the federal level. While this dynamic holds, the cannabis industry will be subject to legislative and regulatory risks. It’s important to understand and evaluate the legal considerations as you do your own research and absorb research from others while finding cannabis stocks with promise and growth potential.

Valuation can also be tricky in a new industry. Many cannabis companies are just getting started, so like all newer companies, they’re attractive in-part because of their potential.  Assessing the future growth and profitability of a company with a limited track record, in a new industry poses its own risk. It is also why these investments have such high upside potential. Most investors feel confident that the future holds tremendous growth, some consolidation, and even companies that lose out to the competition. Being on the side where your equity holding is either bought at a premium by an acquiring company or that within your portfolio you own a future giant (the next Coke, Microsoft, GM of the industry) is the home run many cannabis investors are seeking.

Commoditization is another risk. Just like milk, crude oil, or soybeans, marijuana is a commodity. While the cannabis industry is expected to grow, if supply outpaces demand, prices could fall. Think of the oil-related businesses in 2020. Price risk is a longer-term consideration.

Take-Away

New industries offer incredible potential for investors that spot winners. The cannabis industry has many segments. All of them seem to be on the rise, but there are a lot of companies joining and competing in each of the segments. There will be winners and losers. Understanding the changing regulatory environment and digesting true, non-hype unbiased research on the industry and individual companies helps increase success.

Suggested Reading:

Why Researching Investment Ideas is Important Small Cap Names in a Big Crypto Market



Managing Investment Portfolio Risk Lithium Ion Battery Recycling Heats Up


 

Sources:

https://www.globenewswire.com/news-release/2020/12/01/2137727/0/en/Legal-Marijuana-Market-Growth-is-Expanding-over-17-8-by-2027.html#:~:text=01%2C%202020%20(GLOBE%20NEWSWIRE),during%20period%202020%20to%202027.

https://www.precedenceresearch.com/legal-marijuana-market

Stay up to date. Follow us:

           


Stay up to date. Follow us:

Lineage Cell Therapeutics (LCTX) – Q4 2020 EPS: Catalysts Rich 2021 Ahead

Friday, March 12, 2021

Lineage Cell Therapeutics (LCTX)
Q4 2020 EPS: Catalysts Rich 2021 Ahead

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical programs are in markets with billion dollar opportunities and include three allogeneic (“off-the-shelf”) product candidates: (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; and (iii) VAC, an allogeneic dendritic cell therapy platform for immuno-oncology and infectious disease, currently in clinical development for the treatment of non-small cell lung cancer. For more information, please visit www.lineagecell.com or follow the Company on Twitter @LineageCell.

Ahu Demir, Ph. D., Biotechnology Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Full Year 2020 financials. Lineage reported net loss of $20.6 million or ($0.14) EPS. The company has $41.6 million cash, cash equivalents, and marketable securities as of December 31, 2020. Total revenues were $1.8 million and total operating loss was $27.9 million – $12.3 million in R&D expenses and $15.6 million in SG&A expenses. We estimated $1.9 million in revenue, $12.3 million in R&D expenses, and $16.9 million in SG&A expenses and implemented the changes in our model. The company also had a good start to the year with the sale of additional marketable securities resulting in net proceedings above $21 million. With this, the company now has $57 million in cash only (161 million shares outstanding) bringing cash runway to 2023.

    Value-generating inflection points.  We expect multiple inflection points to generate value for the shares in 2021 selected catalysts include a) Interim data analysis from Cohort 4 OpRegen program 3-months data in Q1 and 6-months data at the annual Association for Research in Vision and Ophthalmology (ARVO) meeting on May 1-7, b) conducting regenerative medicine advanced therapy (RMAT) meeting with …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Release – electroCore Inc. (ECOR) – Announces Fourth Quarter and Full Year 2020 Financial Results


electroCore Announces Fourth Quarter and Full Year 2020 Financial Results

 

Full year 2020 net sales of approximately $3.5 million increased 46% over $2.4 million for full year 2019
Further reduced net cash usage to $3.7 million in the fourth quarter 2020 versus $4.1 million in the third quarter 2020
Ended 2020 with cash and cash equivalents of $22.6 million, excluding $6.9 million raised subsequent to the end of the year
Company to host conference call and webcast today, March 11, 2021 at 4:30pm ET

ROCKAWAY, N.J., March 11, 2021 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced fourth quarter and full year 2020 financial results and provided an operational update.

Fourth Quarter 2020 and Recent Highlights

  • Reported full year 2020 net sales of approximately $3.5 million, representing an increase of 46% over $2.4 million for full year 2019; fourth quarter net sales of approximately $928,000, an increase of 38% over the fourth quarter of 2019;
  • Used net cash of approximately $3.7 million, down from $4.1 million in the third quarter of 2020 and $9.4 million in the fourth quarter of 2019;
  • Secured unique CMS Level II HCPCS reimbursement code for “Non-invasive vagus nerve stimulator”;
  • Announced inclusion of gammaCore in new NHS England and NHS Improvement MedTech Funding Mandate Policy 2021/22, and two-year extension of gammaCore listing in the NHS Supply Chain Catalogue;
  • Announced Scottish Health Technology Group recommendation for use of gammaCore™ in NHS Scotland cluster headache patients;
  • Executed distribution agreements with Pro Medica Baltic, RSK Medical and Medistar for distribution of gammaCore Sapphire in Eastern Europe, Canada and Australia, respectively;
  • Obtained 510(k) clearance of gammaCore to expand its indication into preventative and acute treatment of adolescent migraine (ages 12-17);
  • Announced completion of enrollment in the investigator-initiated SAVIOR-1 clinical trial evaluating gammaCore Sapphire CV in hospitalized COVID-19 patients exhibiting respiratory symptoms;
  • Announced publication of a peer reviewed paper entitled: “Non-Invasive vagus nerve stimulation to reduce ileus after major colorectal surgery: Early development study” in the journal Colorectal Disease on use of nVNS to reduce post-operative ileus after major colorectal surgery;
  • Announced selection of gammaCore for NIDA-sponsored study in opioid use disorders;
  • Announced full enrollment in study of gammaCore for the acute treatment of stroke supported by the Turkish Neurological Society; and
  • Presented positive topline results from the PREMIUM II study evaluating gammaCore for the prevention of migraine subsequent to early trial termination in March 2020 due to COVID-19.

“Dan Goldberger, Chief Executive Officer of electroCore, commented: “We had a highly productive fourth quarter across all facets of our business in spite of the challenges and headwinds of the pandemic. We delivered 38% year-over-year revenue growth in the quarter, we achieved a major U.S. reimbursement milestone in the establishment of a unique Level II HCPCS code for ‘Non-invasive vagus nerve stimulator’, we signed three ex–U.S. distribution agreements, we continued expanding the gammaCore indication for use to include adolescents suffering from migraine, we saw the progression of clinical trials in four additional indications: COVID-19, stroke, post-operative ileus and opioid use disorder, and we realized continued support by NHS England to cover gammaCore therapy through inclusion in the new NHS Improvement MedTech Funding Mandate.

“Notably, we were able to achieve all of this while continuing to manage our cash prudently. Our net cash usage for the fourth quarter of $3.7 million was down from $4.1 million in the third quarter of 2020 and down significantly from $9.4 million in the same period last year. Our cash balance at December 31, 2020 provides substantial runway to execute our plan into 2022.

“Looking ahead, while the course of the pandemic remains difficult to predict, I believe we have taken steps to ensure continued growth of gammaCore in our core revenue generating channels while working to establish and capitalize on new opportunities. I believe gammaCore has broad potential utility across a very diverse range of indications, and along with the entire electroCore team, I remain committed to making this therapy available to every individual who can potentially benefit from it.”

See the full press release at electroCore’s website: investor.electrocore.com

Investors:
Hans Vitzthum
LifeSci Advisors
617-430-7578
hans@lifesciadvisors.com

Media Contact:
Summer Diaz
electroCore
816-401-6333
summer.diaz@electrocore.com

Source: electroCore, Inc.

Palladium One Mining Inc. (NKORF)(PDM:CA) – Accelerating Progress on Multiple Fronts

Friday, March 12, 2021

Palladium One Mining Inc. (NKORF)(PDM:CA)
Accelerating Progress on Multiple Fronts

Palladium One Mining Inc is a palladium dominant, PGE, nickel, copper exploration and development company. Its assets consist of the Lantinen Koillismaa and Kostonjarvi PGE-Cu-Ni projects, located in north-central Finland and the Tyko Ni-Cu-PGE and Disraeli PGE-Ni-Cu properties in Ontario, Canada. LK is targeting disseminated sulphide along 38 kilometers of favorable basal contact. The KS project is targeting massive sulphide within a 20,000-hectare land package covering a regional scale gravity and magnetic geophysical anomaly. Tyko is a 13,000-hectare project targeting disseminated and massive sulphide in a highly metamorphosed Archean terrain. Disraeli is a 2,500-hectare project targeting PGE-rich disseminated and massive sulphide in a highly productive Proterozoic mid-continent rift.

Mark Reichman, Senior Research Analyst of Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Expanded drill program in 2021. Palladium One expects to spend roughly $11.5 million on exploration in 2021. The program will include resource definition drilling at the Kaukua South and Haukiaho zones while drilling eastern and western extensions of Kaukua South. At the Tyko project, activities will focus on new target development, infill drilling, and the expansion of nickel mineralization at the Smoke Lake zone. The company expects to complete the Phase II drill program at the Lantinen Koillismaa (LK) project and begin a 12,000-meter Phase III drilling program in the second half of the year. This year’s program will also entail 2,000 meters of infill drilling at the Haukiaho zone. In Canada, 2,000 meters of drilling is planned for the Tyko project, along with 1,500 meters of drilling at the Disraeli project. An NI 43-101 resource estimate of Kaukua South is expected to be complete in the first half of 2022.

    Infill drilling at Kaukua South.  Infill drilling has revealed continuous mineralization over 1,300 meters into an area that looked less promising based on geophysics thus indicating greater potential for open pit resources at the Kaukua South zone of the LK project. Thirty four holes totaling 6,404 meters have been drilled to date on Kaukua South as part of the 17,500-meter Phase II program …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Entravision Communications Corporation – (EVC) A Remarkable Quarter Raising Price Target

Friday, March 12, 2021

Entravision Communications Corporation (EVC)
A Remarkable Quarter; Raising Price Target

Entravision Communications Corporation is a diversified Spanish-language media company utilizing a combination of television and radio operations to reach Hispanic consumers across the United States, as well as the border markets of Mexico. Entravision owns and/or operates 53 primary television stations and is the largest affiliate group of both the top-ranked Univision television network and Univision’s TeleFutura network, with television stations in 20 of the nation’s top 50 Hispanic markets. The Company also operates one of the nation’s largest groups of primarily Spanish-language radio stations, consisting of 48 owned and operated radio stations.

Michael Kupinski, Director of Research, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Q4 overachieves expectations. Total company revenues were $171.7 million versus our $140.7 million expectation, driven by strong growth at its recent acquisition of Cisneros, which benefited from strong advertising demand on Facebook in Latin America. Cash flow, as measured by adjusted EBITDA, beat expectations as well, $32.6 million versus our $28.0 million estimate.

    Q1 outlook appears strong.  Favorable operating momentum at Cisneros appears to be continuing into Q1. While the company purchased Cisneros in October for what was believed to be 8 times cash flow, given the significantly improved fundamentals, the multiple appears to be below 4 times. Television and Radio core advertising trends appear to be improving as well. As such, we are raising our Q1 revenue …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Comtech (CMTL) 2Q21 – Results Ahead of Plan, but Full Year 2021 Expectations Unchanged

Friday, March 12, 2021

Comtech (CMTL)
2Q21 Results Ahead of Plan, but Full Year 2021 Expectations Unchanged

Comtech Telecommunications Corp. engages in the design, development, production, and marketing of products, systems, and services for advanced communications solutions in the United States and internationally. It operates in three segments: Telecommunications Transmission, Mobile Data Communications, and RF Microwave Amplifiers. The Telecommunications Transmission segment provides satellite earth station equipment and systems, over-the-horizon microwave systems, and forward error correction technology, which are used in various commercial and government applications, including backhaul of wireless and cellular traffic, broadcasting (including HDTV), IP-based communications traffic, long distance telephony, and secure defense applications. The Mobile Data Communications segment provides mobile satellite transceivers, and computers and satellite earth station network gateways and associated installation, training, and maintenance services; supplies and operates satellite packet data networks, including arranging and providing satellite capacity; and offers microsatellites and related components. The RF Microwave Amplifiers segment designs, develops, manufactures, and markets satellite earth station traveling wave tube amplifiers (TWTA) and broadband amplifiers. Its amplifiers are used in broadcast and broadband satellite communication; defense applications, such as telecommunications systems and electronic warfare systems; and commercial applications comprising oncology treatment systems, as well as to amplify signals carrying voice, video, or data for air-to-satellite-to-ground communications. The company serves satellite systems integrators, wireless and other communication service providers, broadcasters, defense contractors, military, governments, and oil companies. Comtech markets its products through independent representatives and value-added resellers. The company was founded in 1967 and is headquartered in Melville, New York.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    2Q21 Results. Comtech reported revenue of $161.3 million, flat with the $161.7 million reported last year. Adjusted EBITDA came in at $18.1 million compared to $21.2 million last year. EPS was $0.17 and adjusted EPS was $0.27 compared to $0.14 and $0.32, respectively, last year. Management had guided 2Q21 to $135-$140 million of revenue and adjusted EBITDA of $12.5-$14 million. We had forecast revenue of $138 million, adjusted EBITDA of $12.7 million, and adjusted EPS of $0.08.

    UHP Acquisition.  Last week, Comtech finally completed the acquisition of UHP Networks, which was first announced in November 2019. Unfortunately, the Russian operations were not included. UHP provides Comtech with a broader product offering especially in the VSAT market. UHP’s addressable market is multiple times larger than Comtech’s existing satellite ground station solutions …



This research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Information Services (III) – Better than Expected 4Q20 Results

Friday, March 12, 2021

Information Services (III)
Better than Expected 4Q20 Results

ISG (Information Services Group) (Nasdaq: III) is a leading global technology research and advisory firm. A trusted business partner to more than 700 clients, including more than 70 of the top 100 enterprises in the world, ISG is committed to helping corporations, public sector organizations, and service and technology providers achieve operational excellence and faster growth. The firm specializes in digital transformation services, including automation, cloud and data analytics; sourcing advisory; managed governance and risk services; network carrier services; strategy and operations design; change management; market intelligence and technology research and analysis. Founded in 2006, and based in Stamford, Conn., ISG employs more than 1,300 digital-ready professionals operating in more than 20 countries—a global team known for its innovative thinking, market influence, deep industry and technology expertise, and world-class research and analytical capabilities based on the industry’s most comprehensive marketplace data. For more information, visit www.isg-one.com

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    4Q20 Results. Revenue of $66.4 million, up 8% sequentially and up 1% year over year, although down 1% on a constant currency basis. Excluding the impact of reimbursable T&E, revenues were up 5%, y-o-y. Adjusted EBITDA of $9 million, up 11% sequentially and down slightly from the $9.2 million in the 4Q19. EPS of $0.03 versus $0.04. Adjusted EPS of $0.10 flat with the year ago period. We had projected revenue of $56 million, adjusted EBITDA of $7.4 million, EPS of $0.04, and adjusted EPS of $0.07. Consensus called for revenue of $56.2 million and EPS of $0.06.

    Behind the Beat.  Solid sequential revenue growth in the Americas and Europe drove results. Americas revenue was up 8% sequentially and 6% y-o-y. Europe was up 10% sequentially and 1% y-o-y. Clients continued to seek out ways to become more efficient while setting up to prosper in the new digital environment. Digital revenues topped 50% of total revenue and recurring revenues hit 33% of the …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Release – Palladium One Mining (NKORF)(PDM:CA) – Drilling at Kaukua South Extends Mineralization Into Gap Zone


Palladium One Drilling at Kaukua South Extends Mineralization Into “Gap Zone”

 

March 11, 2021 –
Toronto, Ontario –
Infill drilling spaced at 100-meter grid spacing has increased continuous mineralization to over 1,300 meters and into the ‘gap zone’, thereby supporting the thesis of potentially more open-pit resources at the Kaukua South zone of the Läntinen Koillismaa (“LK”) PGE-Ni-Cu project in Finland said Palladium One Mining Inc. (“Palladium One” or the “Company”) (TSXV: PDM, FRA: 7N11, OTC: NKORF) today. These interim results are from the 17,500-meter, Phase II Resource Definition drill program at Kaukua South.

Derrick Weyrauch, President and CEO of Palladium One said, “Drilling at Kaukua South has successfully extended known mineralization to the east and west of hole LK20-016 and into the ‘gap zone’ where the Induced Polarization (“IP”) chargeability anomaly was weaker (see – hole LK20-036 and LK20-044 in Figure 1). These results imply that the ‘gap zone’ could host more mineralization than previously thought. Interim results demonstrate continuity now over 1,300 meters. As a result of continued success, we have accelerated our plans and commenced a new 50-line kilometer IP survey to extend the Kaukua South strike length, which we believe has the potential to be over seven kilometers in length.”

Highlights

  • Infill drilling continues to
    demonstrate continuity of near surface open pit grades and widths.
  • Core zones up to 9.0 meters grading 3.1 g/t
    Palladium equivalent
    (“Pd_Eq.”) within 32.7 meters grading 2.0 g/t
    Pd_Eq.
    in hole LK21-034.
  • First drilling in the “gap zone” returns up to 17.0
    meters grading 1.38 g/t Pd_Eq
    . in hole LK21-044 demonstrating continuity of the mineralization in the Kaukua South IP anomaly.
  • A new IP survey has been initiated to extend the Kaukua South zone from a drill defined four-kilometer strike length to potentially over seven kilometers.
  • 34 holes totaling 6,404 meters
    have been drilled to date on Kaukua South
    as part of the 17,500-meter Phase II program.

Kaukua South Infill Drilling

Kaukua South infill drilling continues to demonstrate consistent near surface open pit grades and widths. A total of 13 holes from the Phase II drill program on Kaukua South have now been released with intersections of up to 53 meters at 2.1
g/t Pd_Eq*, and a core interval of up to 25 meters at 2.9 g/t Pd_Eq.
in hole LK21-028 (see press release January 18, 2021). These 13 holes cover approximately 1.3 kilometers of the Kaukua South Zone, and have returned very similar widths and grades to those in the Kaukua Open Pit resource. (Figure 1 and 2).

Of particular interested is holes LK20-036 and LK20-044 (Figure 2). These represent the first drill holes drilled in the central area of the Kaukua South chargeability anomaly. This central or “gap zone “is approximately a one-kilometer long zone of lower chargeability. The results from these two holes, plus visual results from three additional holes with assays pending, prove that palladium-rich mineralization does extend into this gap zone, which significant increases the potential size of a future Kaukua South resource.

New IP Survey

IP has proven to be highly successful at outlining palladium-rich disseminated copper-nickel sulphide mineralization on the LK Project, the discovery of Kaukua South in an overburden covered area with no previous drilling was a direct result of the Company’s 2020 IP survey.

The success of the Phase II drill program has prompted to the Company to accelerate plans for an additional 50-line kilometre IP survey and a 640-line kilometer drone magnetic survey. The prime objective is to extend the Kaukua South IP chargeability anomaly at least two kilometers to the east onto the Kaukuanjarvi Permit Application area. Regional airborne magnetic data strongly suggests that favourable Kaukua-style mafic-ultramafic hosts rocks extend into this area.

Additionally, the Company believes there is potential to extend Kaukua South at least one kilometer west of the existing 2020 survey grid.  The Company plans to re-survey and expand the historic 2008 IP survey which encountered several technical challenges, resulting in amongst other issues, detecting only half of the mineralization associated with the Kaukua Open Pit Resource (Figure 1).

Taken together these two new IP grids could potentially extend the Kaukua South IP chargeability anomaly to over seven kilometers.

Figure 1. Greater Kaukua area plan map, showingcurrent NI 43-101 Kaukua Deposit conceptual pit outline (dashed yellow), Kaukua South and Murtolampi IP chargeability anomalies, and Palladium One drill hole locations. Holes labels in red form part of this release.

Figure 2. Kaukua South Long section looking north

Table 1: Phase II infill drill results to date on Kaukua South

Zone

Hole

From
(m)

To
(m)

Width
(m)

Pd_Eq
g/t*

PGE g/t
(Pd+Pt+Au)

Pd
g/t

Pt
g/t

Au
g/t

Cu
%

Ni
%

Kaukua
South

LK20-027

103.4

155.0

51.6

1.98

1.07

0.72

0.27

0.08

0.17

0.15

 

Inc.

105.6

113.0

7.4

2.58

1.34

0.90

0.31

0.13

0.26

0.18

 

And

149.5

155.0

5.5

3.12

1.96

1.34

0.52

0.10

0.27

0.17

 

Inc.

153.5

155.0

1.5

6.14

4.09

2.79

1.15

0.15

0.56

0.28

Kaukua
South

LK20-028

42.6

95.5

52.9

2.06

1.44

1.00

0.36

0.08

0.11

0.11

 

Inc.

46.9

72.0

25.1

2.92

2.08

1.44

0.52

0.12

0.17

0.14

 

Inc.

50.5

60.0

9.5

3.56

2.52

1.75

0.61

0.16

0.23

0.16

Kaukua
South

LK20-029

37.5

62.9

25.4

2.57

1.87

1.30

0.46

0.11

0.15

0.11

 

Inc.

47.0

62.0

15.0

3.16

2.36

1.65

0.58

0.13

0.17

0.13

 

Inc.

56.5

62.0

5.5

4.34

3.36

2.36

0.82

0.18

0.20

0.16

 

Inc

56.5

57.7

1.2

6.15

4.97

3.54

1.26

0.17

0.25

0.21

Kaukua
South

LK20-030

26.4

86.5

60.1

1.88

1.00

0.68

0.24

0.07

0.17

0.14

 

Inc.

47.0

68.0

21.0

2.44

1.43

0.98

0.35

0.10

0.21

0.16

 

Inc.

53.0

54.5

1.5

3.94

2.69

1.78

0.78

0.12

0.28

0.20

Kaukua
South

LK20-031

17.9

61.5

43.6

1.94

1.12

0.76

0.27

0.09

0.16

0.13

 

Inc.

17.9

55.5

37.6

2.17

1.25

0.85

0.30

0.10

0.19

0.14

 

Inc.

24.5

35.0

10.5

2.81

1.60

1.09

0.39

0.11

0.27

0.18

Kaukua
South

LK20-032

60.3

108.3

48.0

1.81

0.84

0.57

0.21

0.06

0.16

0.16

 

Inc.

61.4

75.0

13.7

2.12

0.90

0.58

0.23

0.09

0.22

0.20

Kaukua
South

LK20-033

41.3

85.0

43.7

1.76

0.87

0.58

0.21

0.07

0.18

0.14

 

Inc.

42.7

56.3

13.7

2.33

1.21

0.83

0.28

0.10

0.21

0.18

Kaukua South

LK20-034

86.9

119.5

32.7

2.05

1.16

0.81

0.26

0.09

0.16

0.15

 

Inc.

88.5

112.5

24.0

2.26

1.32

0.93

0.29

0.10

0.17

0.15

 

Inc.

88.5

97.5

9.0

3.06

1.98

1.41

0.45

0.12

0.20

0.17

 

Inc.

94.5

96.0

1.5

4.20

2.94

2.15

0.66

0.14

0.25

0.20

Kaukua South

LK20-035

66.0

118.0

52.0

1.32

0.63

0.44

0.15

0.04

0.11

0.11

 

Inc

67.5

69.0

1.5

3.49

2.44

2.10

0.27

0.07

0.23

0.15

 

And

95.5

104.7

9.2

2.04

1.23

0.80

0.32

0.11

0.17

0.13

Kaukua South

LK20-036

245.3

280.0

34.6

1.05

0.39

0.25

0.11

0.03

0.10

0.11

 

Inc.

257.5

280.0

22.5

1.17

0.47

0.31

0.12

0.04

0.13

0.11

 

Inc.

259.0

260.5

1.5

1.72

0.86

0.62

0.16

0.07

0.15

0.14

Kaukua South

LK20-042

115.5

158.9

43.4

1.41

0.77

0.53

0.19

0.05

0.09

0.12

 

Inc.

118.5

123.0

4.5

2.29

1.23

0.82

0.32

0.09

0.14

0.19

 

And

133.0

146.5

13.5

1.71

1.04

0.74

0.25

0.06

0.09

0.12

 

Inc.

143.5

146.5

3.0

1.97

1.47

1.13

0.28

0.06

0.08

0.09

Kaukua South

LK20-043

131.5

162.3

30.8

1.24

0.55

0.36

0.15

0.04

0.11

0.12

 

Inc.

133.0

136.0

3.0

2.05

1.16

0.82

0.32

0.02

0.05

0.20

 

And

187.4

188.5

1.1

2.00

1.54

1.09

0.40

0.05

0.07

0.09

Kaukua South

LK20-044

156.8

173.8

17.0

1.38

0.62

0.41

0.14

0.06

0.14

0.12

 

Inc.

156.8

169.5

12.7

1.58

0.71

0.48

0.17

0.07

0.16

0.14

 

Inc.

166.0

169.5

3.4

2.10

1.07

0.73

0.25

0.08

0.20

0.16

* Reported widths are “drilled widths” not true widths.
** Orange shaded values previously released (see press release January 18, 2021)

*Palladium Equivalent
Palladium equivalent is calculated using US$1,100 per ounce for palladium, US$950 per ounce for platinum, US$1,300 per ounce for gold, US$6,614 per tonne for copper, and US$15,4332 per tonne for nickel. This calculation is consistent with the calculation in the Company’s September 2019 NI 43-101 Kaukua resource estimate.

QA/QC
The Phase I drilling program was carried out under the supervision of Neil Pettigrew, M.Sc., P. Geo., Vice President of Exploration and a director of the Company.

Drill core samples were split using a rock saw by Company staff, with half retained in the core box and stored indoors in a secure facility, in Taivalkoski, Finland. The drill core samples were transported by courier from the Company’s core handling facility in Taivalkoski, Finland, to ALS Global (“ALS”) laboratory in Outokumpu, Finland. ALS, is an accredited lab and are ISO compliant (ISO 9001:2008, ISO/IEC 17025:2005). PGE analysis was performed using a 30 grams fire assay with an ICP-MS or ICP-AES finish. Multi-element analyses, including copper and nickel were analysed by four acid digestion using 0.25 grams with an ICP-AES finish.

Certified standards, blanks and crushed duplicates are placed in the sample stream at a rate of one QA/QC sample per 10 core samples. Results are analyzed for acceptance at the time of import. All standards associated with the results in this press release were determined to be acceptable within the defined limits of the standard used.

Qualified Person
The technical information in this release has been reviewed and verified by Neil Pettigrew, M.Sc., P. Geo., Vice President of Exploration and a director of the Company and the Qualified Person as defined by National Instrument 43-101.

About Palladium One
Palladium One Mining Inc. is an exploration company targeting district scale, platinum-group-element (PGE)-copper nickel deposits in Finland and Canada. Its flagship project is the Läntinen Koillismaa or LK Project, a palladium dominant platinum group element-copper-nickel project in north-central Finland, ranked by the Fraser Institute as one of the world’s top countries for mineral exploration and development. Exploration at LK is focused on targeting disseminated sulfides along 38 kilometers of favorable basal contact and building on an established NI 43-101 open pit resource.

ON BEHALF OF THE BOARD
“Derrick
Weyrauch”

President & CEO,
Director

For further information contact: Derrick Weyrauch, President
& CEO

Email: info@palladiumoneinc.com

Neither the TSX Venture Exchange nor its Market Regulator (as
that term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.

This
press release includes “forward-looking information” that is subject
to a few assumptions, risks and uncertainties, many of which are beyond the
control of the Company. Statements regarding listing of the Company’s common
shares on the TSXV are subject to all of the risks and uncertainties normally
incident to such events. Investors are cautioned that any such statements are
not guarantees of future events and that actual events or developments may
differ materially from those projected in the forward-looking statements. Such
forward-looking statements represent management’s best judgment based on
information currently available. Factors that could cause the actual results to
differ materially from those in forward-looking statements include regulatory actions
and general business conditions. Such forward-looking information reflects the
Company’s views with respect to future events and is subject to risks,
uncertainties and assumptions, including those set out in the Company’s annual
information form dated April 29, 2020 and filed under the Company’s profile on
SEDAR at www.sedar.com.
The Company does not undertake to update forward
?looking
statements or forward
?looking information,
except as required by law. Investors are cautioned that any such statements are
not guarantees of future performance and actual results or developments may
differ materially from those projected in the forward-looking statements.

Source: Palladium One Mining Inc.

How Much is a Trillion?

 


$1.9 Trillion in Terms we can Better Relate To

Whether one finds the new $1.9 Trillion Covid Relief Bill heartwarming or blood-boiling is a matter of personal philosophy. What we can all agree on related to the stimulus package, The American Rescue Plan, is that it is a lot of money – a trillion is a very big number that most of us can not even fathom.

Two Ways to
Better Comprehend a Trillion

Rather than just use the word “huge” to describe a trillion, or even $1.9 trillion, I want to put it in terms that are better understood.  Using my trusted HP 12c, I began entering the number one trillion and quickly found that my 20-year-old calculator only allowed for nine zeros — not the required 12 places after the number one. The number I tried to input was a thousand times higher.  I adapted by using 1 x 1012.

We’ve all seen graphics with stacks of money on football fields or bills placed end to end, circling the globe, or to the moon and back; none of those measurements resonated with me. I wanted to try measurements that myself and others are more experienced with, like how long is a year, and more personal and down-to-earth such as heartbeats.

How many dollars a day is a trillion since the year One? The year 1AD was a long time ago. We’ll call it 2020 years ago because rounding down a touch barely changes the end result. Multiplying years by 365, we get 737,700.  Channelchek readers are sharp and would know this is wrong, so I went back and multiplied by 365.25 to account for leap years (which certainly existed then). So the number of days since the year one, before Jesus learned to walk, is 737,805. That’s a lot of days! The question is, how much money per day would you have to collect each day since the calendar switched from BC to AD to hit a trillion? Simple division tells us $1,355,371.68 per day, each and every day (anno domini).

That result, for my digestion, is easier to comprehend; I have a sense of how long a year is and understand millions better than trillions or even billions. Multiplying by 1.9 I learn, the amount of the current stimulus package, if paid back without interest, over 2020 years would equate to daily installments of $2,575,206.19. Wow!

A second way I looked at one trillion is how many dollars per heartbeat over a lifetime would you have to receive in order to have a trillion dollars and also $1.9 trillion. The CDC lists the average life span as 79 years (rounded up from 78.7). The average healthy heartbeat averages 70 per minute. 70 per minute is 4200 per hour, and in 24 hours, 100,800 over a day. Again allowing for leap years, 100,800 x 365.25 is 36,817,200 beats per year.

If you live for only 79 years, you will have had about 2,908,558,800 heart beats according to this math. A quick search around the medical sites tells me that our non-exact science (fuzzy math) largely agrees with theirs. Dividing one trillion into almost 3 billion heartbeats equals 343.81, or by this example, you’d have to receive $343.81 for every heartbeat from your first breath until your last to reach $1 trillion.

 

 

In stimulus package terms (*1.9), The American Rescue Plan is the same dollar amount as an individual’s lifetime of heartbeats at $653.24 per beat.

 

Take-Away

There’s a line in the movie Austin Powers where, after being frozen since the 1960s, the villain, Dr. Evil is thawed and declares he wants to hold the world ransom for “One Million Dollars.” He’s quickly reminded that $1 million is not that big of a deal anymore.  He quickly upped the number. When we hear or see something often, we begin to become numb to what it means, or in the case of large numbers, the true magnitude. Today, billionaires are the new millionaires, and a trillion doesn’t sound like much now that the US is in debt by tens-of-trillions.

Becoming grounded often means understanding what we’re actually looking at. Although the above was fun and surprising for me in some ways, I prefer to look at these large numbers, particularly as it relates to debt in this way. Suppose the full US national debt is $28 trillion while US GDP (the size of the economy) is $22 trillion. That is a debt-to-GDP ratio of 127%, which exceeds World War II levels. The trend in the US, even during the booming Trump years, was not paying down debt but increasing it. This trend is not economically sustainable.

Paul Hoffman

Managing Editor, Channelchek

 

Suggested Reading

The Correlation Between Stocks and Unemployment Who Gets to Participate in Private Offerings?


What is the Future of Entertainment Consumption?

Small Cap Names in a Big Crypto Market


Release – Capstone Turbine (CPST) – Enters Into A New OEM Agreement With European-Based B K


Capstone Turbine Enters Into A New Original Equipment Manufacturer (OEM) Agreement With European-Based Clean Energy Company, B+K – Expanding The Application Of Microturbine Technologies Not Reliant On Fossil Fuels

 

Capstone Immediately Receives Order for First Commercial Unit

VAN NUYS, CA / ACCESSWIRE / March 11, 2021 / Capstone Turbine Corporation (www.capstoneturbine.com) (NASDAQ:CPST), the world’s leading manufacturer of clean energy technology microturbine systems, announced today that it continues to expand the range of non-fossil fuels able to power its innovative microturbine based energy solutions. With the signing of a new OEM agreement with Professor Dr. Berg & Kießling GmbH (B+K) (www.bergundkiessling.com), Capstone immediately received an order for the first Capstone microturbine kit under the new agreement.

The Capstone microturbines will be integrated into the innovative B+K ClinX product. The ClinX product uses renewable sources instead of fossil fuels and thus prevents unnecessary CO2 emissions. ClinX enables the decentralized conversion of previously unused wooden byproducts into heat and electricity. A unique feature of ClinX is its relatively small size of <1 MW, which works well for decentralized energy applications, and it has a broad fuel spectrum. ClinX burns heterogeneous, wooden byproducts and thus converts heat and at the same time produces electricity using the externally fired Capstone microturbine.

 

 

“B+K was founded back in 2012 to develop decentralized combined heat and power (CHP) systems based on microturbine technology, and we are proud that after many years of collaboration, B+K has officially selected Capstone technology for their innovative ClinX product,” said Darren Jamison, Capstone’s President and Chief Executive Officer. “Capstone is committed to finding better ways to generate green energy for distributed generation and CHP applications using renewable natural gas, biogas, hydrogen or externally fired thermal solutions like the B+K ClinX,” Mr. Jamison added.

The ClinX solution provides a more environmentally-friendly solution as customers convert energy from renewable energy sources instead of fossil fuels. This renewable energy generation helps to avoid additional CO2 emissions and to protect the environment. The use of professional filter systems guarantees compliance with stringent air quality standards. Depending on the input, the remaining ashes may also subsequently be used in agriculture and forestry.

“In addition to supplying microturbine kits to B+K, Capstone’s factory project team will support the sale of the ClinX solution with its new Direct Sales organization and with our existing global Distribution network,” said Jim Crouse, Capstone’s Chief Revenue Officer. “The B+K containerized design will allow for quick deployment and easy installation,” Mr. Crouse added.

ClinX is a modular system that is adapted to customers’ requirements. The ClinX 50 will utilize Capstone’s proven C65 microturbine, and the ClinX 150 will incorporate Capstone’s highly reliable C200 microturbine. The systems will be expandable in a user-friendly manner as the central combustion unit with a subsequent energy conversion module will be able to be supplemented by a cooling or water treatment module if required.

“Capstone is a company that excels globally in clean and environmentally-friendly turbine solutions,” said Sebastian Kiessling, Executive Partner of B+K. “Capstone lives our mission statement together with us, and we are looking forward to long-term cooperation and many successful joint projects,” concluded Mr. Kiessling.

About Capstone Turbine Corporation

Capstone Turbine Corporation (www.capstoneturbine.com) (NASDAQ:CPST) is the world’s leading producer of highly efficient, low-emission, resilient microturbine energy systems. Capstone microturbines serve multiple vertical markets worldwide, including natural resources, energy efficiency, renewable energy, critical power supply, transportation and microgrids. Capstone offers a comprehensive product lineup via our direct sales team, as well as our global distribution network. Capstone provides scalable solutions from 30 kWs to 10 MWs that operate on a variety of fuels and are the ideal solution for today’s multi-technology distributed power generation projects.

For customers with limited capital or short-term needs, Capstone offers rental systems; for more information, contact: rentals@capstoneturbine.com. To date, Capstone has shipped nearly 10,000 units to 83 countries and in FY20, saved customers an estimated $219 million in annual energy costs and 368,000 tons of carbon.

For more information about the company, please visit www.capstoneturbine.com. Follow Capstone Turbine on Twitter, LinkedIn, Instagram, Facebook and YouTube.

Cautionary Note Regarding Forward-Looking Statements

This release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including statements regarding expectations, beliefs, plans, intentions and strategies of the Company. The Company has tried to identify these forward-looking statements by using words such as “expect,” “anticipate,” “believe,” “could,” “should,” “estimate,” “intend,” “may,” “will,” “plan,” “goal” and similar terms and phrases, but such words, terms and phrases are not the exclusive means of identifying such statements. Actual results, performance and achievements could differ materially from those expressed in, or implied by, these forward-looking statements due to a variety of risks, uncertainties and other factors, including, but not limited to, the following: the ongoing effects of the COVID-19 pandemic; the availability of credit and compliance with the agreements governing the Company’s indebtedness; the Company’s ability to develop new products and enhance existing products; intense competition; financial performance of the oil and natural gas industry and other general business, industry and economic conditions; the Company’s ability to adequately protect its intellectual property rights; and the impact of pending or threatened litigation. For a detailed discussion of factors that could affect the Company’s future operating results, please see the Company’s filings with the Securities and Exchange Commission, including the disclosures under “Risk Factors” in those filings. Except as expressly required by the federal securities laws, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason. “Capstone” and “Capstone Microturbine” are registered trademarks of Capstone Turbine Corporation. All other trademarks mentioned are the property of their respective owners.

CONTACT:
Capstone Turbine Corporation
Investor and investment media inquiries:
818-407-3628

ir@capstoneturbine.com

SOURCE: Capstone Turbine Corporation

PDS Biotechnology Corp (PDSB) – Versamune-based COVID-19 Vaccine Consortium Received Brazilian Government Grant

Thursday, March 11, 2021

PDS Biotechnology Corp (PDSB)
Versamune-based COVID-19 Vaccine Consortium Received Brazilian Government Grant

PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is primarily engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.

Ahu Demir, Ph. D., Biotechnology Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Supporting funding of $US60 million for the coronavirus program. PDS Biotech, Farmacore, and Blanver consortium received a commitment from the Secretary for Research and Scientific Training of the Ministry of Science, Technology, and Innovation of Brazil (MCTI). The funding of approximately US$60 million will be used to support the clinical development and commercialization of a novel, Versamune-based, second-generation COVID-19 vaccine in Brazil.

    Near-term value-generating catalysts.  We believe the company has multiple inflection points to generate value including a) PDS0101 preliminary efficacy data anticipated in Q2 2021 and b) PDS0203 safety and immunogenicity data projected in Q4 2021/Q1 2022 …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision.